Publications
Detailed Information
Preclinical efficacy of the c-Met inhibitor CE-355621 in a U87 MG mouse xenograft model evaluated by 18F-FDG small-animal PET
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Tseng, Jeffrey R | - |
dc.contributor.author | Kang, Keon Wook | - |
dc.contributor.author | Dandekar, Mangal | - |
dc.contributor.author | Yaghoubi, Shahriar | - |
dc.contributor.author | Lee, Joseph H | - |
dc.contributor.author | Christensen, James G | - |
dc.contributor.author | Muir, Stephen | - |
dc.contributor.author | Gambhir, Sanjiv S | - |
dc.date.accessioned | 2010-06-25T06:55:39Z | - |
dc.date.available | 2010-06-25T06:55:39Z | - |
dc.date.issued | 2007-12-14 | - |
dc.identifier.citation | J Nucl Med. 2008;49(1):129-134 | en |
dc.identifier.issn | 0161-5505 (Print) | - |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18077531 | - |
dc.identifier.uri | http://jnm.snmjournals.org/cgi/reprint/49/1/129.pdf | - |
dc.identifier.uri | https://hdl.handle.net/10371/67813 | - |
dc.description.abstract | The purpose of this study was to evaluate the efficacy of CE-355621, a novel antibody against c-Met, in a subcutaneous U87 MG xenograft mouse model using (18)F-FDG small-animal PET. METHODS: CE-355621 or control vehicle was administered intraperitoneally into nude mice (drug-treated group, n = 12; control group, n = 14) with U87 MG subcutaneous tumor xenografts. Drug efficacy was evaluated over 2 wk using (18)F-FDG small-animal PET and compared with tumor volume growth curves. RESULTS: The maximum %ID/g (percentage injected dose per gram of tissue) of (18)F-FDG accumulation in mice treated with CE-355621 remained essentially unchanged over 2 wk, whereas the %ID/g of the control tumors increased 66% compared with the baseline. Significant inhibition of (18)F-FDG accumulation was seen 3 d after drug treatment, which was earlier than the inhibition of tumor volume growth seen at 7 d after drug treatment. CONCLUSION: CE-355621 is an efficacious novel antineoplastic chemotherapeutic agent that inhibits (18)F-FDG accumulation earlier than tumor volume changes in a mouse xenograft model. These results support the use of (18)F-FDG PET to assess early tumor response for CE-355621. | en |
dc.language.iso | en | - |
dc.publisher | The Society of Nuclear Medicine Inc | en |
dc.subject | Animals | en |
dc.subject | Antibodies, Monoclonal/*pharmacology | en |
dc.subject | Antineoplastic Agents/*pharmacology | en |
dc.subject | Cell Line, Tumor | en |
dc.subject | Drug Antagonism | en |
dc.subject | Fluorodeoxyglucose F18/*pharmacokinetics | en |
dc.subject | Glioblastoma | en |
dc.subject | Humans | en |
dc.subject | Mice | en |
dc.subject | Mice, Nude | en |
dc.subject | Neoplasm Transplantation | en |
dc.subject | Positron-Emission Tomography/methods | en |
dc.subject | Proto-Oncogene Proteins c-met/*antagonists & inhibitors | en |
dc.subject | Radiopharmaceuticals/*pharmacokinetics | en |
dc.subject | Transplantation, Heterologous | en |
dc.title | Preclinical efficacy of the c-Met inhibitor CE-355621 in a U87 MG mouse xenograft model evaluated by 18F-FDG small-animal PET | en |
dc.type | Article | en |
dc.contributor.AlternativeAuthor | 강건욱 | - |
dc.identifier.doi | 10.2967/jnumed.106.038836 | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.